Injectable GLP-1 Mechanism: Subcutaneous Injection: When you inject semaglutide or tirzepatide under the skin: Medication forms depot: Creates a small reservoir under the skin Slow absorption: Gradually releases into bloodstream over days Steady drug levels: Maintains consistent therapeutic concentration for one week Nearly complete bioavailability: Almost all medication reaches systemic circulation Predictable dosing: Precise amount of medication absorbed Why This Works So Well: Bypasses digestive system completely No breakdown by stomach acid or enzymes Consistent absorption across patients Once-weekly dosing maintains stable drug levels Can use relatively small doses for maximum effect Oral GLP-1 Mechanism (Rybelsus): Tablet Absorption Process: When you swallow Rybelsus: SNAC creates temporary window: Absorption enhancer raises stomach pH and increases permeability Limited absorption time: 30-minute window before medication moves to small intestine Most medication destroyed: Stomach acid and enzymes break down 99%+ of semaglutide Small amount reaches bloodstream: Less than 1% absorbed Rapid clearance: Daily dosing needed to maintain any therapeutic level Why This Is Challenging: Requires much higher doses (14 mg oral vs 2.4 mg injectable weekly) Strict timing requirements Variable absorption between patients Food, beverages, and other medications interfere with absorption Still less effective despite higher doses Pharmacokinetic Comparison: Absorption Challenges for Oral Peptides: Size Matters: GLP-1 medications are large molecules (peptides with 30-40 amino acids)
Dose strengths: Wegovy injection comes in five dose strengths : 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg
Some grey market sources claim to offer it, but these carry significant risks
the caution applies particularly to inhaled or intravenous NAC, which may occasionally trigger bronchospasm
Emerging metabolic research shows that GLP-1 also interacts with organs involved in energy balance, including the liver, brain, and adipose tissue
